Bone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint

Similar documents
2010 Hematopoietic and Lymphoid ICD-O Codes - Alphabetical List THIS TABLE REPLACES ALL ICD-O-3 Codes

2012 Hematopoietic and Lymphoid ICD-O Codes - Numerical List THIS TABLE REPLACES ALL ICD-O-3 Codes

Non-Hodgkin Lymphoma. Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract.

Bone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint

Combinations of morphology codes of haematological malignancies (HM) referring to the same tumour or to a potential transformation

Bone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint

The College of American Pathologists offers these protocols

Integrated Hematopathology. Morphology and FCI with IHC

Classification of Hematologic Malignancies. Patricia Aoun MD MPH

Introduction: The Revised (4 th Edition) World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues

Reviewing the ICD-10 classification of haematological neoplasms on its way to ICD-11

WHO Classification. B-cell chronic lymphocytic leukemia/small T-cell granular lymphocytic leukemia

Practical Diagnosis of Hematologic Disorders. Vol 2 Malignant Disorders

Changes to the Hematopoietic and Lymphoid Neoplasm Coding Manual

Lymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital

During past decades, because of the lack of knowledge

Contractor Name: Novitas Solutions, Inc. Contractor Number: Contractor Type: MAC A. LCD ID Number: L35032 Status: A-Approved

HEMATOLOGIC MALIGNANCIES BIOLOGY

Clinical Policy: Bendamustine (Bendeka, Treanda) Reference Number: PA.CP.PHAR.307

Hematology Page 1 of 8

Contents. vii. Preface... Acknowledgments... v xiii

Protocol for the Examination of Specimens From Patients With Hematopoietic Neoplasms Involving the Bone Marrow*

THE SOCIETY FOR Hematopathology and the European

Hepatic Lymphoma Diagnosis An Algorithmic Approach

The primary medical content categories of the blueprint are shown below, with the percentage assigned to each for a typical exam:

HEMATOPATHOLOGY (SHANDS HOSPITAL AT THE UNIVERSITY OF FLORIDA): Rotation Director: Ying Li, M.D., Ph.D., Assistant Professor

Classifications of lymphomas

Hematology Unit Lab 2 Review Material

Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms. Daniel A. Arber, MD Stanford University

3.1 Introduction. It is emphasised that not all tests are necessarily required in every case. 3.2 Taxonomic structure

2 nd step do Bone Marrow Study If possible both the aspiration and

Corrigenda. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (revised 4th edition): corrections made in second print run

HEMATOLOGY Maintenance of Certification (MOC) Examination Blueprint

DETERMINATION OF A LYMPHOID PROCESS

MOC HEM - General Hematopathology (Mandatory 50-Question Module)

MOC HEM - General Hematopathology (Mandatory 50-Question Module)

Protocol for the Examination of Specimens From Patients With Hematopoietic Neoplasms Involving the Bone Marrow

Large cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s

88-year-old Female with Lymphadenopathy. Faizi Ali, MD

Clinical Policy: Bendamustine (Bendeka, Treanda) Reference Number: CP.PHAR.307

Differential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital

Pathology of Hematopoietic and Lymphoid tissue

155.2 Malignant neoplasm of liver not specified as primary or secondary. C22.9 Malignant neoplasm of liver, not specified as primary or secondary

Recommended Curriculum for Teaching Hematopathology to Subspecialty Hematopathology Fellows

Pathology of Hematopoietic and Lymphoid tissue

Myeloid malignancies Chronic myeloid disorders

Small B-cell (Histologically Low Grade) Lymphoma

Pathology. #11 Acute Leukemias. Farah Banyhany. Dr. Sohaib Al- Khatib 23/2/16

Beyond the CBC Report: Extended Laboratory Testing in the Evaluation for Hematologic Neoplasia Disclosure

Commentary. N. L. Harris, 1 E. S. Jaffe, 2 J. Diebold, 3 G. Flandrin, 4 H. K. Muller-Hermelink, 5 J.Vardiman, 6 T. A. Lister 7 & C. D.

The spectrum of flow cytometry of the bone marrow

SAUDI FELLOWSHIP TRAINING PROGRAM. Adult Haematology. Final Written Examination 2019

COPYRIGHTED MATERIAL. Introduction CHAPTER 1. Examination of p atients. Classification of c utaneous l ymphomas. Staging i nvestigations

Protocol for the Examination of Hematologic Malignancies in Bone Marrow

12 Dynamic Interactions between Hematopoietic Stem and Progenitor Cells and the Bone Marrow: Current Biology of Stem Cell Homing and Mobilization

2016 WHO CLASSIFICATION OF TUMOURS OF HAEMATOPOIETIC AND LYMPHOID TISSUES, 4TH ED., VOL FCDS WEBCAST SERIES OCTOBER 19, 2017

Recommended Timing for Transplant Consultation

B980 B968. C836 Diffuse non-hodgkin's lymphoma, undifferentiated (diffuse) C839 Non-follicular diffuse non-hodgkin lymphoma, unspecified

Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section:

A.C. Feller. J. Diebold Histopathology of Nodal and Extranodal Non-Hodgkin's Lymphomas

Ordering Physician CLIENT,CLIENT. Collected REVISED REPORT

Change Summary - Form 2018 (R3) 1 of 12

Adult Acute leukemia. Matthew Seftel. August

a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation

Plasma cell myeloma (multiple myeloma)

Cutaneous Lymphoid Proliferations: A Comprehensive Textbook of Lymphocytic Infiltrates of the Skin

Saudi Fellowship Training Program. Final Written Examination of Adult Hematology 2018

INDEX. Numbers in italics refer to pages on which tables appear. Numbers in boldface refer to pages on which images appear.

WHO Classification of Myeloid Neoplasms with Defined Molecular Abnormalities

Non-Hodgkin s Lymphomas Version

Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)

癌症診療準則與核心測量 - 淋巴瘤 彰化基督教醫院內科部血液腫瘤科張正雄. Agenda

Lymphoid Neoplasms. Sylvie Freeman Department of Clinical Immunology, University of Birmingham

2007 Workshop of Society for Hematopathology & European Association for Hematopathology Indianapolis, IN, USA Case # 228

2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes

Lymphatic system component

Protocol applies to specimens from patients with Wilms tumor (nephroblastoma) or other renal tumors of childhood.

Immunopathology of Lymphoma

WHO Classification 7/2/2009

Hematopoietic Neoplasms Best Coding Practices Edition

Burkitt lymphoma. Sporadic Endemic in Africa associated with EBV Translocations involving MYC gene on chromosome 8

Protocol applies to melanoma of cutaneous surfaces only.

74y old Female with chronic elevation of Platelet count. August 18, 2005 Faizi Ali, MD Hematopathology Fellow

Small Intestine. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition

Eosinophilia: A Diagnostic Approach and Test Utilization Strategies for Bone Marrow Evaluation

3/5/2013. Hematopoiesis: Red and white marrow. Hematopoiesis. Bone marrow aspirate and core biopsy. Gartner, Color Textbook of Histology, 3 rd Edition

LYMPHOMAS an overview of some subtypes of NHLs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Thyroid Gland. Protocol applies to all malignant tumors of the thyroid gland, except lymphomas.

Clinical Utility. Clinical Utility of the Automated IG-Count Xavier Troussard

Lymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC

1. Challenging cases of eosinophilia (peripheral, bone marrow, or lymph node/tissue-based) falling into any of the following categories

2013 Pathology Student

Session 5. Pre-malignant clonal hematopoietic proliferations. Chairs: Frank Kuo and Valentina Nardi

Pathology of the Hematopoietic System

The Power of Peripheral Blood Smears: Apparent Diagnostic Clues (Part 1) (Wednesday, October 19, 2011)

Transcription:

Bone Marrow Protocol applies to acute leukemias, myelodysplastic syndromes, myeloproliferative disorders, chronic lymphoproliferative disorders, malignant lymphomas, plasma cell dyscrasias, histiocytic and dendritic cell neoplasms and mastocytosis. Protocol revision date: January 2005 No AJCC/UICC staging system Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint Authors LoAnn C. Peterson, MD Department of Pathology, Northwestern Memorial Hospital, Chicago, Illinois Steven J. Agosti, MD James A. Haley VA Hospital, University of South Florida, Tampa, Florida James Hoyer, MD Hematopathology, Mayo Clinic, Rochester, Minnesota For the Members of the Hematology and Clinical Microscopy Resource Committee and the Cancer Committee, College of American Pathologists

Bone Marrow Hematologic System CAP Approved 2005. College of American Pathologists. All rights reserved. The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the College. The College of American Pathologists offers these protocols to assist pathologists in providing clinically useful and relevant information when reporting results of surgical specimen examinations of surgical specimens. The College regards the reporting elements in the Surgical Pathology Cancer Case Summary (Checklist) portion of the protocols as essential elements of the pathology report. However, the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice. The College developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the checklist elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with the document. At the same time, the College cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document. 2

CAP Approved Hematologic System Bone Marrow Summary of Changes to Checklist(s) Protocol revision date: January 2005 No changes have been made to the data elements of the checklist(s) since the January 2004 protocol revision. 3

Bone Marrow Hematologic System CAP Approved Surgical Pathology Cancer Case Summary (Checklist) BONE MARROW: Blood Film, Aspirate, Cell Block, Trephine Biopsy, Touch Imprint Patient name: Hematopathology/Surgical pathology number: Note: Check 1 response unless otherwise indicated. Protocol revision date: January 2005 Applies to hematopoietic and lymphoid disorders of the bone marrow only No AJCC/UICC staging system MACROSCOPIC Specimen Type Aspirate Biopsy Both aspirate and biopsy Blood film Cell block (clot section) Not specified *Biopsy Site * Not applicable * Right posterior iliac crest * Left posterior iliac crest * Other (specify): * Not specified *Aspirate Site * Not applicable * Right posterior iliac crest * Left posterior iliac crest * Sternum * Other (specify): * Not specified 4

CAP Approved Hematologic System Bone Marrow Adequacy of Specimen Satisfactory Limited Unsatisfactory Phenotyping Performed, see separate report Performed Specify method and results: Not performed Cytogenetics Performed (see separate report) Performed Specify results: Not performed Disease Type (WHO Classification) (check all that apply) Chronic Myeloproliferative Diseases Chronic myelogenous leukemia Chronic neutrophilic leukemia Chronic eosinophilic leukemia/hypereosinophilic syndrome Polycythemia vera Chronic idiopathic myelofibrosis Essential thrombocythemia Myeloproliferative disease, unclassifiable Myelodysplastic/Myeloproliferative Diseases Chronic myelomonocytic leukemia Atypical chronic myeloid leukemia Juvenile myelomonocytic leukemia Myelodysplastic/myeloproliferative disease, unclassifiable Myelodysplastic Syndromes Refractory anemia Refractory anemia with ringed sideroblasts Refractory cytopenia with multilineage dysplasia Refractory cytopenia with multilineage dysplasia and ringed sideroblasts Refractory anemia with excess blasts (RAEB) RAEB-1 RAEB-2 Myelodysplastic syndrome, unclassifiable Myelodysplastic syndrome associated with isolated del(5q) 5

Bone Marrow Hematologic System CAP Approved Acute Myeloid Leukemias (AMLs) Acute myeloid leukemia with recurrent genetic abnormalities AML with t(8;21)(q22;q22) AML with abnormal bone marrow eosinophils inv(16) or t(16;16) or t(16;16)(p13;q22);cbfβ/myh11) Acute promyelocytic leukemia t(15;17)(q22;q12) and variants AML with 11q23 (MLL) abnormality Acute myeloid leukemia with multilineage dysplasia Following a myelodysplastic syndrome or myelodysplastic syndrome/myeloproliferative disorder Without antecedent myelodysplastic syndrome Acute myeloid leukemia and myelodysplastic syndromes, therapy-related Alkylating agent-related Topoisomerase type II inhibitor-related (some may be lymphoid) Other types (specify): Acute myeloid leukemia not otherwise categorized AML minimally differentiated AML without maturation AML with maturation Acute myelomonocytic leukemia Acute monoblastic and monocytic leukemia Acute erythroid leukemia Acute megakaryoblastic leukemia Acute basophilic leukemia Acute panmyelosis with myelofibrosis Myeloid sarcoma Acute leukemia of ambiguous lineage Undifferentiated acute leukemia Bilineal acute leukemia Biphenotypic acute leukemia Precursor B-cell and T-cell Neoplasms Precursor B lymphoblastic leukemia/lymphoblastic lymphoma Precursor T lymphoblastic leukemia/lymphoblastic lymphoma 6

CAP Approved Hematologic System Bone Marrow Mature B-cell Neoplasms Chronic lymphocytic leukemia/small lymphocytic lymphoma B-cell prolymphocytic leukemia Lymphoplasmacytic lymphoma Splenic marginal zone lymphoma Hairy cell leukemia Plasma cell myeloma Monoclonal gammopathy of undetermined significance (MGUS) Solitary plasmacytoma of bone Extraosseus plasmacytoma Primary amyloidosis Heavy chain disease Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT-lymphoma) Nodal marginal zone B-cell lymphoma Follicular lymphoma Grade 1 Grade 2 Grade 3 Mantle cell lymphoma Diffuse large B-cell lymphoma Mediastinal (thymic) large B-cell lymphoma Primary effusion lymphoma Burkitt lymphoma / leukemia B-cell Proliferations of Uncertain Malignant Potential Lymphomatoid granulomatosis Post-transplant lymphoproliferative disorder, polymorphic 7

Bone Marrow Hematologic System CAP Approved Mature T-cell and NK-cell Neoplasms Leukemic / Disseminated T-cell prolymphocytic leukemia T-cell large granular lymphocytic leukemia Aggressive NK-cell leukemia Adult T-cell leukemia/lymphoma Cutaneous Mycosis fungoides Sézary syndrome Primary cutaneous anaplastic large cell lymphoma Lymphomatoid papulosis Other Extranodal Extranodal NK/T-cell lymphoma, nasal-type Enteropathy-type T-cell lymphoma Hepatosplenic T-cell lymphoma Subcutaneous panniculitis-like T-cell lymphoma Nodal Angioimmunoblastic T-cell lymphoma Peripheral T-cell lymphoma, unspecified Anaplastic large cell lymphoma Neoplasm of Uncertain Lineage and Stage of Differentiation Blastic NK-cell lymphoma Hodgkin Lymphoma Nodular lymphocyte predominant Hodgkin lymphoma Classical Hodgkin lymphoma Nodular sclerosis classical Hodgkin lymphoma Lymphocyte-rich classical Hodgkin lymphoma Mixed cellularity classical Hodgkin lymphoma Lymphocyte-depleted classical Hodgkin lymphoma Histiocytic and Dendritic-cell Neoplasms Histiocytic sarcoma Langerhans cell histiocytosis Langerhans cell sarcoma Interdigitating dendritic cell sarcoma / tumor Follicular dendritic cell sarcoma / tumor Dendritic cell sarcoma, not otherwise specified 8

CAP Approved Hematologic System Bone Marrow Mastocytosis Indolent systemic mastocytosis Systemic mastocytosis with associated clonal, hematologic non-mast-cell lineage disease Aggressive systemic mastocytosis Mast cell leukemia Mast cell sarcoma Other Malignant neoplasm, type cannot be determined *Additional Pathologic Findings *Specify: *Comment(s) 9